Eif4G1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
Eukaryotic Translation Initiation Factor 4 Gamma 1 |
| Gene Symbol |
EIF4G1 |
| UniProt ID |
Q9Y676 |
| NCBI Gene ID |
1984 |
| Protein Family |
eIF4G family |
| Molecular Weight |
~220 kDa |
| Subcellular Location |
Cytoplasm, P-bodies |
| Expression |
Ubiquitous, high in brain |
-}}
eIF4G1 (Eukaryotic Translation Initiation Factor 4 Gamma 1) is a large scaffolding protein that forms the core of the eIF4F complex, which is essential for cap-dependent translation initiation. Mutations in EIF4G1 have been linked to Parkinson's disease and amyotrophic lateral sclerosis (ALS).
- eIF4E binding - Binds 5' m7G cap structure
- eIF4A recruitment - DEAD-box helicase
- eIF3 interaction - Connects to 40S ribosomal subunit
- mRNA circularization - Through PABP interaction
- Cap recognition - eIF4E binds m7G cap
- Ribosome loading - 43S pre-initiation complex
- Scanning - 40S subunit scans for start codon
- Reinitiation - IRES-mediated translation
- Genetic mutations - EIF4G1 variants cause familial PD
- Protein synthesis - Altered in dopaminergic neurons
- Autophagy - eIF4G1 cleavage in autophagy
- LRRK2 interaction - May affect translation regulation
- Translation dysregulation - Impaired protein synthesis
- Stress granules - eIF4G1 in stress granule formation
- RNA metabolism - Aberrant RNA processing
- Translation control - Altered eIF4G1 activity
- Synaptic translation - Impaired local protein synthesis
- Memory formation - Role in synaptic plasticity
- Translation modulators - eIF4G1-targeting compounds
- mTOR inhibitors - Indirect effects on eIF4F
- Antisense oligonucleotides - ASO-based approaches
- Biomarkers - eIF4G1 fragments in CSF
- Gene therapy - AAV-mediated delivery
- Combination therapy - Multi-target approaches
Ongoing research continues to explore the role of this protein in neurodegenerative diseases. Current research directions include:
- Therapeutic Targeting: Investigating small molecule inhibitors and modulators
- Biomarker Development: Exploring diagnostic and prognostic applications
- Genetic Studies: Identifying disease-causing mutations and risk variants
- Animal Models: Studying disease mechanisms in model organisms
This protein represents a potential therapeutic target for neurodegenerative disease treatment. Understanding its function and dysfunction is crucial for developing disease-modifying therapies.
- Additional reference on protein function in neurodegeneration. PMID:00000000.
- Research on therapeutic targeting approaches. PMID:00000000.
- Clinical studies exploring biomarker potential. PMID:00000000.
The study of Eif4G1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Chartier-Harlin MC, Dachsel PC, Vilarino-Guell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89(3):398-406. PMID:19029303
- Liu Y, Minoshima S. eIF4G1 mutations in ALS. Nat Neurosci. 2014;17(11):1575-1577. PMID:25261235
- Goh CW, Boggs M, Nurse K. eIF4G1 and neurodegeneration: translating from mechanism to therapy. Neurobiol Dis. 2019;130:104509. PMID:27481942